MFN Drug Pricing Targets: Lowering U.S. Drug Co...

By Rene Pretorius

May 21, 2025

Summary The U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) have set Most-Favored-Nation (MFN)
A System Dynamics Approach to Lowering Drug Prices by 30–80% in the US
FDA AI Drug Approval
Trump Science Publishing Critique: Analyzing Political Interference and Metho...
South Africa NHI Bill Court Ruling Calls for Scrutiny
Assessing Risks and Opportunities: The Impact of the CDC Hepatitis Lab Closure
Defunding Scientific Research: Implications and Misconceptions in GawandeR...
Advancing Early Childhood Health: PureHealth’s Partnership with Abu Dha...
South Africa Cannabis Regulations: Government Withdraws Ban for New Framework...
Trump Healthcare Policy Changes: Reversing Biden’s Executive Orders and...
Advancing EU Health Technology Assessment: Insights from the HAG Meeting
Medicare Drug Negotiations Target Ozempic and Ibrance for Price Cuts
CMS Price Negotiations: Bridging the Gap in US Drug Pricing